Hospital
Sebring Health Services, LLC
Sebring Health Services, LLC was paid $4.09M by Medicaid between Jan 2018 and Dec 2024, across 100 billing codes. Its largest line is 99283, emergency room visit (moderate) — 40% of everything it billed.
33Billing provider infoSEBRING HEALTH SERVICES, LLC
SEBRING, FL 33870
SEBRING, FL 33870
33aNPI1598282246assigned 08/24/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.09M
24GClaims167,845
24DCodes billed100
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#91 of 163
Median peer was paid$4.77M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,690 | $145K | |
| 2019 | 32,602 | $366K | |
| 2020 | 27,929 | $304K | |
| 2021 | 30,048 | $740K | |
| 2022 | 32,836 | $1.17M | |
| 2023 | 20,502 | $825K | |
| 2024incomplete | 12,238 | $536K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 40% | 19,183 | 17,240 | $1.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 10,692 | 9,245 | $671K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.2% | 3,799 | 3,536 | $335K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.2% | 1,306 | 1,151 | $211K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.5% | 1,845 | 1,506 | $184K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.4% | 2,358 | 1,623 | $141K |
| 80053 | Comprehensive metabolic panel | 2.5% | 9,346 | 7,484 | $104K |
| G0378 | Hospital observation service, per hour | 2.2% | 1,275 | 600 | $89K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 786 | 751 | $82K |
| 87070 | 1.6% | 2,214 | 2,006 | $67K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 514 | 471 | $47K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 746 | 686 | $46K |
88 more codes
| 84703 | 1.1% | 4,350 | $45K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 4,475 | $41K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 433 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,497 | $28K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,664 | $27K |
| J3490 | Unclassified drugs | <1% | 799 | $24K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,198 | $22K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,535 | $20K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,673 | $19K |
| 81001 | <1% | 5,611 | $15K | |
| 85027 | <1% | 12,123 | $14K | |
| 81003 | <1% | 2,866 | $13K | |
| A9270 | Non-covered item or service | <1% | 4,224 | $13K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 509 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 205 | $12K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 175 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,350 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,692 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 645 | $8K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,189 | $7K |
| 84484 | <1% | 3,003 | $6K | |
| 74018 | <1% | 304 | $6K | |
| 85610 | <1% | 2,283 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 940 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,593 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,101 | $5K |
| 85730 | <1% | 1,941 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,617 | $4K |
| 83735 | <1% | 2,202 | $4K | |
| 83690 | <1% | 1,992 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 108 | $4K |
| 73610 | <1% | 84 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,402 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 43 | $3K |
| 87430 | <1% | 1,885 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 226 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 273 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 167 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 741 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,032 | $2K |
| 87077 | <1% | 223 | $2K | |
| 87205 | <1% | 142 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,076 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 284 | $2K |
| 87040 | <1% | 964 | $2K | |
| 84702 | <1% | 80 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 928 | $2K |
| 82550 | <1% | 793 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 136 | $2K |
| 73630 | <1% | 70 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,778 | $1K |
| 83880 | <1% | 1,167 | $1K | |
| 85378 | <1% | 384 | $1K | |
| 80061 | Lipid panel | <1% | 307 | $1K |
| 86850 | <1% | 54 | $1K | |
| 82150 | <1% | 324 | $1K | |
| 73620 | <1% | 12 | $918.23 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 40 | $895.68 |
| 82553 | <1% | 30 | $772.91 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,452 | $720.37 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,445 | $686.18 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $652.87 |
| 73130 | <1% | 25 | $569.17 | |
| 87807 | <1% | 616 | $508.22 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 110 | $500.00 |
| 83605 | <1% | 609 | $492.67 | |
| 86900 | <1% | 167 | $451.30 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $395.34 |
| 73030 | <1% | 15 | $344.41 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 124 | $243.10 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 161 | $242.94 |
| 82948 | <1% | 47 | $229.04 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 600 | $187.08 |
| 80076 | <1% | 54 | $154.63 | |
| 97597 | <1% | 29 | $125.80 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,179 | $92.38 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 249 | $50.00 |
| 86901 | <1% | 153 | $30.33 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 272 | $24.21 |
| 80320 | <1% | 81 | $13.24 | |
| 84100 | <1% | 13 | $3.54 | |
| 87081 | 0% | 15 | $0.00 | |
| 82077 | 0% | 195 | $0.00 | |
| 86140 | 0% | 16 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 79 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 43 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 53 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCAPOTE, HENRY (CFO)